Romiplostim, Alzheimer's drugs in large group of Japanese approvals
This article was originally published in Scrip
A large group of products has received formal final approval from Japan's ministry of health, labour and welfare after a series of positive opinions over the past few months, with the new clearances including several important new therapies for rare disorders and Alzheimer's disease.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.